Marea Therapeutics is a clinical-stage biotech company utilizing medical achievements in human genetics to develop medicines for cardiometabolic diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/18/2024 | Series A | $37.11MM | $xx.xx | $6.18B | Third Rock Ventures | |
Price per Share
$xx.xx
Shares Outstanding
37,106,366
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Third Rock Ventures
|
||||||
06/18/2024 | Series B | $152.89MM | $xx.xx | $26.73B | Alpha Wave Global, Citadel, Forbion Capital Partners, Omega Funds, Perceptive Advisors, Sofinnova Investments, Third Rock Ventures, Venbio | |
Price per Share
$xx.xx
Shares Outstanding
105,443,886
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alpha Wave Global, Citadel, Forbion Capital Partners, Omega Funds, Perceptive Advisors, Sofinnova Investments, Third Rock Ventures, Venbio
|